<DOC>
	<DOCNO>NCT00115765</DOCNO>
	<brief_summary>The purpose study ass whether treatment study drug , panitumumab give concomitantly every 2 ( Q2 ) week oxaliplatin-based chemotherapy bevacizumab improve progression-free survival ( PFS ) compare treatment Q2-week oxaliplatin-based chemotherapy bevacizumab alone . All subject receive Q2-week oxaliplatin- irinotecan-based chemotherapy bevacizumab . Control arm subject receive concomitant panitumumab therapy .</brief_summary>
	<brief_title>PACCE : Panitumumab Advanced Colorectal Cancer Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adenocarcinoma colon rectum Metastatic colorectal cancer ( mCRC ) Measurable disease per modify response evaluation criterion solid tumor ( RECIST ) criterion ECOG performance status 0 1 Available paraffinembedded tumor tissue ( primary tumor metastasis ) unstained slide paraffinembedded tissue If history primary cancer , subject eligible : Curatively resect nonmelanomatous skin cancer ; Curatively treat cervical carcinoma situ ; Other primary solid tumor curatively treat know active disease present treatment administer last 5 year . Adequate hematologic data follow : Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9 cells/L ; Platelet count great equal 100 x 10^9/L ; Hemoglobin great equal 9.0 g/dL . Adequate renal function : Serum creatinine less equal 1.5 x upper limit normal ( ULN ) ; Urinary protein dipstick less 2+ ( urinary dipstick 2+ great , excretion less equal 1000 mg protein per day determine 24hour urine collection ) . Adequate hepatic function : Alkaline phosphatase less equal 3 x ULN ( liver metastasis , less equal 5 x ULN ) ; Aspartate aminotransferase ( serum glutamicoxaloacetic transaminase ) ( AST ) less equal 3 x ULN ( liver metastasis , less equal 5 x ULN ) ; Alanine aminotransferase ( serum glutamicpyruvic transaminase ) ( ALT ) less equal 3 x ULN ( liver metastasis , less equal 5 x ULN ) ; Bilirubin le equal 2 x ULN . Competent comprehend , sign , date IRBapproved inform consent form Before studyspecific procedure , appropriate write informed consent must obtain . Prior chemotherapy biologic ( i.e. , antibody vaccine ) treatment mCRC disease Last dose adjuvant radiosensitizing chemotherapy le 6 month randomization Radiotherapy within 14 day randomization Elective and/or plan major surgical procedure perform course trial ( surgery arise need necessary course study , agree priori , make subject ineligible ) Major surgery within 28 day randomization Central nervous system metastases History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest Xray CTscan Clinically significant ascites Preexisting bleed diathesis coagulopathy need fulldose anticoagulation Any follow within 1 year randomization : Myocardial infarction ; Unstable angina ; Symptomatic congestive heart failure ; Serious uncontrolled cardiac arrhythmia ; Cerebrovascular accident transient ischemic attack ; Gastrointestinal ulcer hemorrhage ; Hemoptysis ; Pulmonary embolism ; Deep vein thrombosis , significant thromboembolic event . Regular use nonsteroidal antiinflammatory agent Female subject childbearing potential , abstinent , willing use contraceptive course study 6 month follow last dose firstline treatment Female subject breastfeed positive serum pregnancy test 72 hour prior randomization Male subject , abstinent , willing use adequate contraception upon enrollment study 6 month follow last dose firstline treatment Subject know human immunodeficiency virus ( HIV ) positive Subject allergic panitumumab component panitumumab formulation History medical psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation study drug administration may interfere conduct study interpretation study result Subject unwilling unable comply study requirement Any kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Panitumumab Advanced Colorectal Cancer Evaluation Study ( PACCE Study )</keyword>
	<keyword>Colorectal , Colon , Rectal Cancer , Metastatic Colorectal</keyword>
	<keyword>Cancer</keyword>
	<keyword>EGFr , Clinical Trial</keyword>
	<keyword>Panitumumab , ABX-EGF</keyword>
	<keyword>Immunex , Abgenix , Amgen</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Oncology</keyword>
</DOC>